156 related articles for article (PubMed ID: 36992433)
1. A Novel and Simplified Score for Determining Treatment Eligibility for Patients with Chronic Hepatitis B.
Geeratragool T; Tangkijvanich P; Nimanong S; Chainuvati S; Charatcharoenwitthaya P; Tanwandee T; Chotiyaputta W
Viruses; 2023 Mar; 15(3):. PubMed ID: 36992433
[No Abstract] [Full Text] [Related]
2. Performance of risk estimation for hepatocellular carcinoma in chronic hepatitis B (REACH-B) score in classifying treatment eligibility under 2012 Asian Pacific Association for the Study of the Liver (APASL) guideline for chronic hepatitis B patients.
Chen TM; Chang CC; Huang PT; Wen CF; Lin CC
Aliment Pharmacol Ther; 2013 Jan; 37(2):243-51. PubMed ID: 23171385
[TBL] [Abstract][Full Text] [Related]
3. Assessment and Simplification of Treatment Eligibility Among Patients With Chronic Hepatitis B Infection in Vietnam.
Vu Hai V; Shimakawa Y; Kim J; Do Ngoc H; Le Minh Q; Laureillard D; Lemoine M
Clin Infect Dis; 2021 Sep; 73(5):e1072-e1077. PubMed ID: 33331880
[TBL] [Abstract][Full Text] [Related]
4. Development of a simple score based on HBeAg and ALT for selecting patients for HBV treatment in Africa.
Shimakawa Y; Njie R; Ndow G; Vray M; Mbaye PS; Bonnard P; Sombié R; Nana J; Leroy V; Bottero J; Ingiliz P; Post G; Sanneh B; Baldeh I; Suso P; Ceesay A; Jeng A; Njai HF; Nayagam S; D'Alessandro U; Chemin I; Mendy M; Thursz M; Lemoine M
J Hepatol; 2018 Oct; 69(4):776-784. PubMed ID: 30104154
[TBL] [Abstract][Full Text] [Related]
5. Development and evaluation of a simple treatment eligibility score (HEPSANET) to decentralise hepatitis B care in Africa: a cross-sectional study.
Minier N; Guingané AN; Okeke E; Sinkala E; Johannessen A; Andersson MI; Davwar P; Desalegn H; Duguru M; Fall F; Mboup S; Maponga T; Matthews PC; Ramírez Mena A; Ndow G; Orlien SMS; Riches N; Seydi M; Sonderup M; Spearman CW; Stockdale AJ; Taljaard J; Vinikoor M; Wandeler G; Lemoine M; Shimakawa Y; Sombié R
Lancet Gastroenterol Hepatol; 2024 Apr; 9(4):323-332. PubMed ID: 38367633
[TBL] [Abstract][Full Text] [Related]
6. Accuracy of international guidelines for identifying significant fibrosis in hepatitis B e antigen--negative patients with chronic hepatitis.
Sanai FM; Babatin MA; Bzeizi KI; Alsohaibani F; Al-Hamoudi W; Alsaad KO; Al Mana H; Handoo FA; Al-Ashgar H; Alghamdi H; Ibrahim A; Aljumah A; Alalwan A; Altraif IH; Al-Hussaini H; Myers RP; Abdo AA
Clin Gastroenterol Hepatol; 2013 Nov; 11(11):1493-1499.e2. PubMed ID: 23811251
[TBL] [Abstract][Full Text] [Related]
7. Three heads are better than two: Hepatitis B core-related antigen as a new predictor of hepatitis B virus-related hepatocellular carcinoma.
Wu JW; Kao JH; Tseng TC
Clin Mol Hepatol; 2021 Oct; 27(4):524-534. PubMed ID: 33618507
[TBL] [Abstract][Full Text] [Related]
8. Simplifying Treatment Criteria in Chronic Hepatitis B: Reducing Barriers to Elimination.
Wong RJ; Kaufman HW; Niles JK; Kapoor H; Gish RG
Clin Infect Dis; 2023 Feb; 76(3):e791-e800. PubMed ID: 35594550
[TBL] [Abstract][Full Text] [Related]
9. Increasing on-treatment hepatocellular carcinoma risk with decreasing baseline viral load in HBeAg-positive chronic hepatitis B.
Choi WM; Kim GA; Choi J; Han S; Lim YS
J Clin Invest; 2022 May; 132(10):. PubMed ID: 35358094
[TBL] [Abstract][Full Text] [Related]
10. NIH consensus development statement on management of hepatitis B.
Belongia EA; Costa J; Gareen IF; Grem JL; Inadomi JM; Kern ER; McHugh JA; Petersen GM; Rein MF; Sorrell MF; Strader DB; Trotter HT
NIH Consens State Sci Statements; 2008 Oct 22-24; 25(2):1-29. PubMed ID: 18949020
[TBL] [Abstract][Full Text] [Related]
11. Nucleos(t)ide Analogue Treatment for Patients With Hepatitis B Virus (HBV) e Antigen-Positive Chronic HBV Genotype C Infection: A Nationwide, Multicenter, Retrospective Study.
Chang Y; Choe WH; Sinn DH; Lee JH; Ahn SH; Lee H; Shim JJ; Jun DW; Park SY; Nam JY; Cho EJ; Yu SJ; Lee DH; Lee JM; Kim YJ; Kwon SY; Paik SW; Yoon JH
J Infect Dis; 2017 Dec; 216(11):1407-1414. PubMed ID: 29029102
[TBL] [Abstract][Full Text] [Related]
12. Prediction models of long-term cirrhosis and hepatocellular carcinoma risk in chronic hepatitis B patients: risk scores integrating host and virus profiles.
Lee MH; Yang HI; Liu J; Batrla-Utermann R; Jen CL; Iloeje UH; Lu SN; You SL; Wang LY; Chen CJ;
Hepatology; 2013 Aug; 58(2):546-54. PubMed ID: 23504622
[TBL] [Abstract][Full Text] [Related]
13. A novel nomogram to predict evident histological liver injury in patients with HBeAg-positive chronic hepatitis B virus infection.
Chang X; Wang J; Chen Y; Long Q; Song L; Li Q; Liu H; Shang Q; Yu Z; Jiang L; Xiao G; Li L; Chen L; Wang X; Li Z; Chen D; Dong Z; An L; Tan L; Chen Y; Yang Y
EBioMedicine; 2021 May; 67():103389. PubMed ID: 34004423
[TBL] [Abstract][Full Text] [Related]
14. CLINICAL PHASES OF CHRONIC HEPATITIS B AMONG GEORGIAN PATIENTS.
Zakalashvili M; Butsashvili M; Zarkua J; Abzianidze T; Kamkamidze G; Metreveli D
Georgian Med News; 2022 Jan; (322):26-29. PubMed ID: 35134754
[TBL] [Abstract][Full Text] [Related]
15. Relationship between virological response and FIB-4 index in chronic hepatitis B patients with entecavir therapy.
Li N; Xu JH; Yu M; Wang S; Si CW; Yu YY
World J Gastroenterol; 2015 Nov; 21(43):12421-9. PubMed ID: 26604649
[TBL] [Abstract][Full Text] [Related]
16. Incorporating Serum Level of Hepatitis B Surface Antigen or Omitting Level of Hepatitis B Virus DNA Does not Affect Calculation of Risk for Hepatocellular Carcinoma in Patients Without Cirrhosis.
Yang HI; Tseng TC; Liu J; Lee MH; Liu CJ; Su TH; Batrla-Utermann R; Chan HL; Kao JH; Chen CJ
Clin Gastroenterol Hepatol; 2016 Mar; 14(3):461-468.e2. PubMed ID: 26598229
[TBL] [Abstract][Full Text] [Related]
17. Treatment recommendations for chronic hepatitis B: an evaluation of current guidelines based on a natural history study in the United States.
Tong MJ; Hsien C; Hsu L; Sun HE; Blatt LM
Hepatology; 2008 Oct; 48(4):1070-8. PubMed ID: 18688879
[TBL] [Abstract][Full Text] [Related]
18. Nomograms for risk of hepatocellular carcinoma in patients with chronic hepatitis B virus infection.
Yang HI; Sherman M; Su J; Chen PJ; Liaw YF; Iloeje UH; Chen CJ
J Clin Oncol; 2010 May; 28(14):2437-44. PubMed ID: 20368541
[TBL] [Abstract][Full Text] [Related]
19. Real-World Effectiveness From the Asia Pacific Rim Liver Consortium for HBV Risk Score for the Prediction of Hepatocellular Carcinoma in Chronic Hepatitis B Patients Treated With Oral Antiviral Therapy.
Yang HI; Yeh ML; Wong GL; Peng CY; Chen CH; Trinh HN; Cheung KS; Xie Q; Su TH; Kozuka R; Lee DH; Ogawa E; Zhao C; Ning HB; Huang R; Li J; Zhang JQ; Ide T; Xing H; Iwane S; Takahashi H; Wong C; Wong C; Lin CH; Hoang J; Le A; Henry L; Toyoda H; Ueno Y; Gane EJ; Eguchi Y; Kurosaki M; Wu C; Liu C; Shang J; Furusyo N; Enomoto M; Kao JH; Yuen MF; Yu ML; Nguyen MH
J Infect Dis; 2020 Jan; 221(3):389-399. PubMed ID: 31550363
[TBL] [Abstract][Full Text] [Related]
20. Moderate levels of serum hepatitis B virus DNA are associated with the highest risk of hepatocellular carcinoma in chronic hepatitis B patients.
Kim GA; Han S; Choi GH; Choi J; Lim YS
Aliment Pharmacol Ther; 2020 Jun; 51(11):1169-1179. PubMed ID: 32291781
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
